{
    "clinical_study": {
        "@rank": "82332", 
        "arm_group": [
            {
                "arm_group_label": "Colesevelam", 
                "arm_group_type": "Active Comparator", 
                "description": "3.75mg/day for 6 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "3.75 mg/day for 6 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "If treatment of colesevelam in conjunction with ezetimibe, will lead to further reduction in\n      plasma plant sterol levels in sitosterolemia patients. We hypothesize that treatment with\n      colesevelam decrease cholesterol absorption and increase cholesterol fractional synthesis in\n      sitosterolemia patients. This hypothesis will be examined by measuring changes in\n      cholesterol absorption and synthesis using isotope technique."
        }, 
        "brief_title": "Effects of Colesevelam", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Sitosterolemia", 
        "condition_browse": {
            "mesh_term": [
                "Hypercholesterolemia", 
                "Intestinal Diseases", 
                "Lipid Metabolism, Inborn Errors"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Confirmed diagnosis of homozygous sitosterolemia as established by genotyping  and/or\n             clinical parameters\n\n          2. Receiving ezetimibe treatment\n\n          3. Over 12 years of age (no maximum)\n\n          4. Concomitant illnesses or conditions\n\n        Exclusion Criteria:\n\n          1. Pregnancy\n\n          2. Intellectual disability\n\n          3. Bowel or biliary obstruction\n\n          4. Known hypersensitivity to colesevelam or any ingredients of colesevelam"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01948648", 
            "org_study_id": "B2013:075"
        }, 
        "intervention": [
            {
                "arm_group_label": "Colesevelam", 
                "intervention_name": "Colesevelam", 
                "intervention_type": "Drug", 
                "other_name": "Lodalis"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other", 
                "other_name": "Sugar Pill"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Colesevelam"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "plant sterols", 
            "cholesterol", 
            "colesevelam", 
            "phytosterolemia"
        ], 
        "lastchanged_date": "September 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Winnipeg", 
                    "country": "Canada", 
                    "state": "Manitoba"
                }, 
                "name": "Richardson Center for Functional Foods and Nutraceuticals"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Colesevelam as an Adjunct Therapy for Sitosterolemia", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "plasma plant sterol assessment using Gas Chromatography(GC)", 
            "measure": "Plasma plant sterol level", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01948648"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "use of stable isotope technique to assess cholesterol absorption", 
                "measure": "Cholesterol absorption", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }, 
            {
                "description": "use of stable isotope to assess cholesterol synthesis", 
                "measure": "cholesterol synthesis", 
                "safety_issue": "No", 
                "time_frame": "16 weeks"
            }
        ], 
        "source": "University of Manitoba", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Manitoba", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}